Baseline Characteristics Module
The Baseline Characteristics Module provides demographic and baseline characteristics information for participants in a clinical trial. This module includes data such as population descriptions and the types of units analyzed, helping researchers understand the baseline characteristics of study participants.
Baseline Characteristics Module path is as follows:
Study -> Results Section -> Baseline Characteristics Module
Baseline Characteristics Module
Ignite Creation Date:
2025-12-24 @ 5:52 PM
Ignite Modification Date:
2025-12-25 @ 3:17 PM
NCT ID:
NCT00530868
Population Description:
Postmenopausal women with newly diagnosed stage 2 or 3 estrogen and/or progesterone receptor-positive, HER2-negative breast cancer were randomly assigned (2:1) between letrozole 2.5 mg PO daily plus bevacizumab 15 mg/ kg IV every 3 weeks (Let/Bev) and letrozole 2.5 mg PO daily (Let) for 24 weeks prior to definitive surgery.
Study:
NCT00530868
Study Brief:
Results Section:
NCT00530868